Hypoxia regulates CD9 expression and dissemination of B lymphoblasts.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
12 2022
Historique:
received: 24 05 2022
revised: 21 09 2022
accepted: 26 09 2022
pubmed: 7 11 2022
medline: 30 11 2022
entrez: 6 11 2022
Statut: ppublish

Résumé

Acute lymphoblastic leukemias (ALL) are the most frequent cancer in children and derive most often from B-cell precursors. Current survival rates roughly reach 90% at 10 years from diagnosis. However, 15-20% of children still relapse with a significant risk of death. Our previous work showed that the transmembrane protein CD9 plays a major role in lymphoblasts migration into sanctuary sites, especially in testis, through the activation of RAC1 signaling upon blasts stimulation with C-X-C chemokine ligand 12 (CXCL12). Here, we identified common factors shared by the bone marrow and extramedullary niches which could upregulate CD9 expression and function. We found that low oxygen levels enhance CD9 expression both at mRNA and protein levels. We further determined that Hypoxia Inducible Factor 1α (HIF1α), the master transcription factor involved in hypoxia response, binds directly CD9 promoter and induce CD9 transcription. We also showed that CD9 protein is crucial for leukemic cell adhesion and migration at low oxygen levels, possibly through its action on RAC1 signaling. Mouse xenograft experiments indicate that HIF1α signaling pathway promotes ALL cells engraftment in a CD9-dependent manner. The present work increments our understanding of CD9 implication in ALL pathogenesis.

Identifiants

pubmed: 36335655
pii: S0145-2126(22)00190-4
doi: 10.1016/j.leukres.2022.106964
pii:
doi:

Substances chimiques

Tetraspanin 29 0
Oxygen S88TT14065
CD9 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106964

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Auteurs

Jérémie Rouger-Gaudichon (J)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France; University Hospital, Caen, Department of Pediatric Oncology and Hematology, CHU Caen Normandie, France. Electronic address: rouger-j@chu-caen.fr.

Elie Cousin (E)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France; University Hospital, Rennes, Pediatric Oncology and Hematology, CHU Rennes, France.

Hélène Jakobczyk (H)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France.

Lydie Debaize (L)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France.

Anne-Gaëlle Rio (AG)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France.

Anne Forestier (A)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France.

Marie-Pierre Arnaud (MP)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France.

Arnaud Villacreces (A)

BRIC (BoRdeaux Institute of on Cology), UMR1312, INSERM, Univ. Bordeaux, F-33000, Bordeaux, France.

Vincent Praloran (V)

Univ. Bordeaux, INSERM, BMGIC, U1035, F33000 Bordeaux, France.

Rodrigo Jacamo (R)

Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Marie-Dominique Galibert (MD)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France; University Hospital, Rennes, Department of Molecular Genetics and Genomic, CHU Rennes, France.

Marie-Bérengère Troadec (MB)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France; Univ Brest, Inserm, EFS, UMR 1078, GGB, F29200 Brest, France; CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, Brest, France.

Virginie Gandemer (V)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes) - UMR 6290, Equipe Expression des Gènes et Oncogenèse, Rennes, France; University Hospital, Rennes, Pediatric Oncology and Hematology, CHU Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH